Glaucoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• VEGF 1
• NRF2 0
• PI3K 0
• STAT3 0
• AMPK 0
• MAPK 0
• AKT 0
• GLP-1 1
• NLRP3 0
• STING 0
• TNF 0
• IL-1 0
• JAK 0
• MMP-9 1
• PPAR 0
• SIRT1 0
• TP53 0
• ACE2 0
• GPX4 0
• IL-6 1
• mTOR 0
• YAP 0
• APOE 0
• BDNF 0
• CD38 0
• CGRP 0
• COX-2 0
• ERK 0
• GIP 0
• HSP90 0
• IL-17 0
• MEK 0
• MYCN 0
• NF1 0
• NMDA 0
• PDGFR 0
• RANKL 0
• RB1 0
• TIM-3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,677 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Inferonasal MIMS® Procedure: Long-Term Follow-Up Extension Study

  NCT06577857· Sanoculis Ltd· Updated 15 Oct 2026

  “The study was terminated following completion of the Week 24 visit. The Week 30 follow-up visit was canceled due to internal company reasons.”Registry text, quoted unchanged. Source

• Terminated

  Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma

  NCT03016156· St. Jude Children's Research Hospital· Updated 15 Sept 2026

  “Accrual was slow.”Registry text, quoted unchanged. Source

• Terminated

  Automated Applanation Tonometry

  NCT05235321· Duke University· Updated 11 Sept 2026

  “device updates needed”Registry text, quoted unchanged. Source

• Suspended

  CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

  NCT06465537· Shanghai BDgene Co., Ltd.· Updated 20 Aug 2026

  “Per the requirement of China regulation.”Registry text, quoted unchanged. Source

• Withdrawn

  Glaucoma Exercise as Medicine Study (GEMS).

  NCT05581498· Johns Hopkins University· Updated 5 Aug 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma

  NCT04499157· Centre Hospitalier Universitaire, Amiens· Updated 12 Jun 2026

  “recruitement difficulties”Registry text, quoted unchanged. Source

• Withdrawn

  Eye Health Intervention Study in Upper Manhattan

  NCT06112431· Columbia University· Updated 29 May 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  Persistence of Glaucoma Patients With Web-Browser-Based Visual Field Test

  NCT05690152· Andrew Pouw, MD· Updated 18 May 2026

  “Study software was discontinued prior to completion of the study. 8 total subjects had been recruited at that time, but none completed the duration of the study period.”Registry text, quoted unchanged. Source

• Terminated

  Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.

  NCT04702789· Laboratorios Sophia S.A de C.V.· Updated 7 May 2026

  “For interests of sponsor.”Registry text, quoted unchanged. Source

• Terminated

  An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.

  NCT06230393· New World Medical, Inc.· Updated 30 Mar 2026

  “Sponsor decision to close this extension study due to reduction in sample size.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

  NCT06629649· University of Alabama at Birmingham· Source

• Management Pediatric Steroid Induced Glaucoma

  NCT04673201· Mansoura University· Source

• Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment

  NCT07341763· University of Waterloo· Source

• The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).

  NCT07413614· KU Leuven· Source

• A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

  NCT07770685· Astellas Pharma Global Development, Inc.· Source

• Glaucoma Screening to Enhance At-Risk Californians' Health

  NCT06854198· University of California, San Francisco· Source

• Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

  NCT07808333· University of Chicago· Source

• A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

  NCT06822738· AbbVie· Source

• Electrical Stimulation for Vision Neuroenhancement in Glaucoma

  NCT06685211· Stanford University· Source

• Unravelling the Effects of Nicotinamide/Pyrroloquinolone Quinone /Citicoline/Homotaurine Fixed Combination on Contrast Sensitivity, Quality of Life, and Reading Performance in Glaucoma

  NCT07861243· Università degli Studi 'G. d'Annunzio' Chieti e Pescara· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 2
• Mendelian Randomization Analysis 24
• CRISPR-Cas Systems 3
• Gene Expression Profiling 15
• Sequence Analysis, RNA 1
• Exome Sequencing 16
• Proteomics 21
• Metabolomics 11
• Mass Spectrometry 4
• Flow Cytometry 7
• Immunohistochemistry 17
• Magnetic Resonance Imaging 21
• Machine Learning 27
• Deep Learning 35
• Cohort Studies 24
• Genome-Wide Association Study 28

• Comparative proteomics of human anterior lens capsules reveals ATP6V1A-associated lysosomal dysregulation in age-related cataract with primary angle-closure glaucoma.

  J Transl Med, Sept 2026

• Canine Tear Proteomics: A New Frontier in Veterinary Ophthalmology.

  Vet Ophthalmol, Sept 2026

• Sex-Dependent Responses in the Retina Proteome to Ocular Hypertension in a Mouse Model of Glaucoma.

  Int J Mol Sci, Aug 2026

• Proteomic Analyses of Early Versus Advanced Primary Open-Angle Glaucoma Uncover Biochemical Signatures Associated With Disease Staging.

  Mol Cell Proteomics, Jul 2026

• Proteomic Profile Analysis of Plasma and Aqueous Humor from Glaucoma and Nonglaucomatous Patients.

  J Ocul Pharmacol Ther, Jul 2026

• Transcending genome-wide association studies to create useful multi-omic views of glaucoma.

  Prog Retin Eye Res, Jul 2026

• Integrative Multi-Omics Analysis Prioritizes Candidate Therapeutic Targets for Primary Open-Angle Glaucoma.

  Int J Mol Sci, May 2026

• Multi-omics panorama of glaucoma: Pathogenesis, biomarkers, and novel therapeutic strategies.

  Surv Ophthalmol, May 2026

• Integrated plasma proteomics and metabolomics reveal immunometabolic pathways and predictive signatures for age-related eye diseases.

  Metabolism, Apr 2026

• Advances in the application of metal-organic frameworks in ophthalmology.

  Biomater Sci, Apr 2026

See which targets of this disease your abstract mentions, and go to the people working on them.